Chronic Obstructive Pulmonary Disease Market

Key Highlights:

 

  • In 2020, the total COPD market size was USD 12,333 million which is expected to rise during the study period (2019–2032).
  • The diagnosed prevalent cases of COPD in the 7MM was 34,640,030 in 2020. These cases are expected to increase throughout the forecast period, i.e., 2021–2032.
  • Obesity companies working in the market are AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others

 

Request a sample to unlock the CAGR for COPD Market.

 

DelveInsight’s ‘Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the COPD, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The COPD market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM COPD market size from 2019 to 2032. The Report also covers current COPD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease (COPD) Disease Understanding and Treatment Algorithm

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

 

In the United States, the term COPD includes two main conditions—emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy. This damage also can destroy the walls of the air sacs, leading to fewer and larger air sacs instead of many tiny ones. If this happens, the amount of gas exchange in the lungs is reduced.

 

The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging.

 

Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients. These symptoms may vary from day to day and may precede the development of airflow limitation by many years.

Continued in the report…..

 

Chronic Obstructive Pulmonary Disease (COPD) Diagnosis

COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Spirometry is required to diagnose in this clinical context; the presence of a post-bronchodilator FEV1/FVC <0.70 confirms the presence of persistent airflow limitation and, thus, COPD in patients with appropriate symptoms and significant exposures to noxious stimuli. The spirometric criterion for airflow limitation remains a post-bronchodilator fixed ratio of FEV1/FVC < 0.70. This criterion is simple and independent of reference values and has been used in numerous clinical trials that form the evidence base from which most treatment recommendations are drawn. It should be noted that the use of the fixed FEV1/FVC ratio to define airflow limitation may result in the more frequent diagnosis of COPD in the elderly and less frequent diagnosis in adults <45 years, especially in mild disease, compared to using a cut-off based on the lower limit of normal (LLN) values for FEV1/FVC.

Continued in the report…..

 

Chronic Obstructive Pulmonary Disease (COPD) Treatment

Many people with COPD have mild forms of the disease for which little therapy is needed other than smoking cessation. Even for more advanced stages of the disease, effective therapy is available that can control symptoms, slow progression, reduce the risk of complications and exacerbations, and improve the ability to lead an active life. The goal in treating COPD is to help the person breathe easier and get back to regular activities; many treatments and lifestyle approaches can help. The patient may also try some natural and alternative treatment options. COPD treatment focuses on relieving symptoms, such as coughing, breathing problems, and avoiding respiratory infections. The treatments are often based on the stages of COPD.

 

There are certain lifestyle changes required to prevent COPD. Quitting smoking is the essential step in any treatment plan for COPD. Stopping smoking can keep COPD from getting worse and reducing the ability to breathe. In addition to this, physical activity can strengthen the muscles that help breathe and improve overall wellness.

 

Pharmacotherapy for COPD consisted of maintenance and reliever medications. Maintenance medications included inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), fixed-dose combination ICS + LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combination ipratropium + albuterol (collectively referred to as ipratropium [IPR]). Reliever medications included short-acting beta-agonist (SABA), oral corticosteroid (OCS), nebulized ipratropium or combination ipratropium–albuterol (collectively referred to as nebulized ipratropium [nebIPR]), and antibiotics.

 

Several kinds of medications are used to treat COPD's symptoms and complications that include bronchodilators, which relax the muscles around the airways. This helps open the airways and makes breathing easier. Most bronchodilators are taken through an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Some of the short-acting and long-acting bronchodilators that are used in management include Albuterol (ProAir HFA, Ventolin HFA, and others), Ipratropium (Atrovent HFA), Levalbuterol (Xopenex), Aclidinium (Tudorza Pressair), Arformoterol (Brovana), Formoterol (Perforomist), etc. In addition, vaccines are generally recommended for the flu and pneumococcal pneumonia since people with COPD are at higher risk for serious problems from these diseases. However, we have not considered the vaccines in the forecast model of COPD.

Continued in the report…..

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of COPD, gender-specific diagnosed prevalent cases of COPD, age-specific diagnosed prevalent cases of COPD, diagnosed prevalent cases of COPD based on severity of airflow limitation, and diagnosed prevalent cases of COPD based on symptoms and exacerbation history in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • The diagnosed prevalent cases of COPD in the 7MM was 34,640,030 in 2020. These cases are expected to increase throughout the forecast period, i.e., 2021–2032.
  • The estimates suggest higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020 which is expected to increase during the forecast period (2021–2032).
  • In 2020, a lower number of males were affected by this disease contributing 6,588,516 total diagnosed prevalent population of COPD in the United States. In comparison, there were 10,867,088 females affected by COPD in 2020, in the US.
  • In the epidemiology model of COPD, there are multiple age groups referred ranging from 18–44 years, 45–54 years, 55–64 years, 64–74 years, and 75+ years, for COPD. In the US, the highest cases were reported in the age group of 55–64 years i.e. 4,601,558, in 2020.
  • The majority of cases of COPD are female in the US. But in EU-5 and Japan the diagnosed cases of COPD in males represents majority of the cases. Overall, in the 7MM, females are predominantly high in number.
  • In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4 criteria, respectively based on severity of airflow limitation.
  • Among total diagnosed prevalent cases of COPD in the US, 53% were acquired by GOLD A based on symptoms and exacerbation history. Rest of the cases were occupied by other types as 27% by GOLD B, 8% by GOLD C and 12% by GOLD D.
  • Among the five major European countries, Germany has the highest diagnosed prevalent population followed by the Italy and the France. On the other hand, Spain had the lowest diagnosed prevalent population.

Chronic Obstructive Pulmonary Disease Prevalence

Country -Wise Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

The epidemiology segment also provides the Chronic Obstructive Pulmonary Disease (COPD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Chronic Obstructive Pulmonary Disease (COPD) Drug Chapters

The drug chapter segment of the Chronic Obstructive Pulmonary Disease (COPD) report encloses the detailed analysis of Chronic Obstructive Pulmonary Disease (COPD) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Chronic Obstructive Pulmonary Disease (COPD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

 

Chronic Obstructive Pulmonary Disease (COPD) Marketed Drugs

 

Duaklir Pressair/Duaklir Genuair (Aclidinium Bromide and Formoterol Fumarate): AstraZeneca/Circassia Pharmaceuticals Inc.

Duaklir (aclidinium bromide/formoterol fumarate 400 µg/12 µg twice-daily) is an approved fixed-dose LAMA/LABA combination of two long-acting bronchodilators – aclidinium bromide is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta-agonist (LABA). The fixed-dose combination was approved by the European Medicines Agency (EMA) in November 2014 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. The pressair is an easy-to-use, multi-dose, breath-activated inhaler with a unique patient feedback mechanism approved in the US for delivering Tudorza (aclidinium bromide). The Pressair inhaler is being used for the development of Duaklir in the US. Outside of the US, the Pressair inhaler is marketed as Genuair.

Products detail in the report…

 

Advair Diskus/Adoair Diskus/Seretide Diskus (Fluticasone Propionate and Salmeterol Xinafoate): GlaxoSmithKline

Advair Diskus is a combination product of fluticasone propionate + salmeterol xinafoate, which is marketed by GlaxoSmithKline. It is available in three different strengths. One active component of Advair Diskus is fluticasone propionate, which acts as a glucocorticoid receptor agonist (ICS). The other active component of Advair Diskus is salmeterol xinafoate, which acts as a beta 2-adrenoceptor agonist (LABA). The generics versions are available in the US and European markets.

Products detail in the report…

Symbicort (Budesonide and Formoterol Fumarate Dihydrate): AstraZeneca

Symbicort (budesonide + formoterol) combines an inhaled corticosteroid and a fast onset, long-acting beta2-agonist for the maintenance of asthma and COPD, including chronic bronchitis and emphysema, which is marketed by AstraZeneca plc. For patients with COPD, the approved dosage of Symbicort is 160/4.5 mcg, two inhalations twice daily. It combines an inhaled corticosteroid and a fast-onset LABA for the maintenance of asthma and COPD either as Symbicort Turbuhaler or Symbicort pMDI (pressurized metered-dose inhaler).

Products detail in the report…

List to be continued in the report…

 

Chronic Obstructive Pulmonary Disease (COPD) Emerging Drugs

 

Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals

REGN3500 is a fully human monoclonal antibody that inhibits interleukin-33 (IL-33), a protein that is believed to play a key role in type 1 and type 2 inflammation. The drug is administered subcutaneously. Preclinical research showed REGN3500 blocked several markers of both types of inflammation. Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation plays an underlying role. REGN3500 is being studied in Phase III trial for chronic obstructive pulmonary disease (COPD), data of which is expected in 2024.

Products detail in the report…

 

Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

Dupixent (dupilumab) is a monoclonal antibody targeting α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. Dupilumab is approved in the US to treat patients aged ≥12 with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. In addition, it is approved for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged ≥12 whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.

Products detail in the report…

 

Tyvaso (Inhaled treprostinil solution): United Therapeutics

Treprostinil’s mechanism of action suggests that treprostinil may effectively treat pulmonary hypertension associated with lung disease, including pulmonary hypertension associated with COPD (WHO Group 3 Pulmonary Hypertension). The use of inhaled treprostinil may be the preferred route of administration for treating pulmonary hypertension (PH) in COPD patients as it provides a high dose of treprostinil to the damaged lungs. The company is currently conducting two Phase III clinical trials of inhaled treprostinil to treat PH hypertension associated with COPD (WHO Group 3 Pulmonary Hypertension).

Products detail in the report…

List to be continued in the report…

Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

COPD prevalence is dramatically increasing worldwide; however, there are few effective therapies, and none of the treatments currently available prevent the progression of the disease or target all of the hallmark features. The development and progression of COPD are heterogeneous, which has hampered the development of new therapies.

 

Moreover, COPD was under-diagnosed and under-treated, with treatments prescribed contrary to guidelines in patients according to their symptoms and risk level. Patients were treated with various non-pharmacological therapies, including lifestyle changes such as smoking cessation and avoiding lung irritants, physical activity, oxygen therapy, pulmonary rehabilitation, surgery, and others and pharmacological therapies such as bronchodilators, inhalers, steroids, and others.

 

But with time, advancing various diagnostic techniques, knowledge of the pathogenesis, course, and prognosis, and new approaches to therapy have dramatically improved the understanding of this important clinical entity. Early identification and prevention and treatment of emerging stages of the disease through smoking cessation and a growing number of bronchoactive drugs promise to change the outcome.

 

Depending on the severity of the COPD, short-acting or long-acting bronchodilators were introduced. Short-acting bronchodilators last about 4–6 h and should be used when needed only. Long-acting bronchodilators last about 12 h or more and are used every day. Patients at risk of exacerbations began to use long-acting anticholinergics (LAMA) or combinations of inhaled long-acting β2-agonists (LABA) and corticosteroids (ICS). The LABA/LAMA combination was suggested for more symptomatic patients and those at greater exacerbation risk. Roflumilast, a phosphodiesterase-4 inhibitor, is an alternative approach to prevent exacerbations in chronic bronchitis and a history of prior exacerbations. Although the overall approach was lauded for its personalized basis, many of the recommendations were not strictly evidence-based. A key limitation of these recommendations reflected the unclear role of ICS in COPD, with evidence suggesting that the widespread use of these agents persists.

 

According to DelveInsight, Chronic Obstructive Pulmonary Disease market in 7MM is expected to change in the study period 2019–2032.

Chronic Obstructive Pulmonary Disease Market Share

Key Findings

  • The COPD therapeutic market in the 7MM was USD 12,333 million in 2020.
  • The Chronic Obstructive Pulmonary Disease therapeutic market in the United States was USD 9,379 million in the year 2020.
  • The United States accounts for the largest Chronic Obstructive Pulmonary Disease market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • The current COPD market is mainly covered by monotherapies, double combinational therapies, and triple combinational therapies of long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids.
  • Expected launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of COPD.
  • Among all the Chronic Obstructive Pulmonary Disease pipeline therapies, Itepekimab, Dupilumab, Benralizumab, and Mepolizumab, are the only biologics that are expected to target the eosinophilic inflammation pool of COPD, and hence are going to face competition which each other.
  • Among the EU5 countries, Germany had the highest Chronic Obstructive Pulmonary Disease market size, while UK had the lowest market size of COPD.
  • The therapeutic market of COPD in Japan was USD 361 million in the year 2020.

 

The United States: Chronic Obstructive Pulmonary Disease Market Outlook

This section provides the total Chronic Obstructive Pulmonary Disease (COPD) market size and; market size by therapies in the United States.

 

EU-5: Chronic Obstructive Pulmonary Disease Market Outlook

The total Chronic Obstructive Pulmonary Disease (COPD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: COPD Market Outlook

The total Chronic Obstructive Pulmonary Disease (COPD) market size and market size by therapies in Japan are provided.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the COPD market or expected to get launched in the market during the forecast period 2021–2032. The analysis covers COPD market uptake by drugs; patient uptake by therapies; and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Obstructive Pulmonary Disease (COPD) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Obstructive Pulmonary Disease (COPD) emerging therapies.

Reimbursement Scenario in Chronic Obstructive Pulmonary Disease (COPD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Chronic Obstructive Pulmonary Disease (COPD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 12,333 million in 2020

Key Companies

AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals

Scope of the Chronic Obstructive Pulmonary Disease Report

  • The report covers the descriptive overview of COPD, explaining its signs and symptoms, causes, classification and currently available therapies.
  • Comprehensive insight has been provided into the COPD epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for COPD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the COPD market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM COPD market.

COPD Market Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the COPD market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence COPD R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
  • Major players are involved in developing therapies for COPD. Launch of emerging therapies will significantly impact the COPD market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Obstructive Pulmonary Disease (COPD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • COPD Pipeline Analysis
  • COPD Market Size and Trends
  • Chronic Obstructive Pulmonary Disease Market Opportunities
  • Impact of upcoming COPD Therapies

Chronic Obstructive Pulmonary Disease (COPD) Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • COPD Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed COPD Market
  • Chronic Obstructive Pulmonary Disease Drugs Uptake

Chronic Obstructive Pulmonary Disease (COPD) Report Assessment

  • Current Treatment Practices
  • Chronic Obstructive Pulmonary Disease Unmet Needs
  • Pipeline Product Profiles
  • Chronic Obstructive Pulmonary Disease Market Attractiveness
  • Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
  • SWOT analysis

Key Questions

COPD Market Insights:

  • What was the COPD’s market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the COPD’s total market size as well as market size by therapies across the 7MM during the forecast period (2021–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest COPD market size during the forecast period (2021–2032)?
  • At what CAGR, the COPD market is expected to grow at the 7MM level during the forecast period (2021–2032)?
  • What would be the COPD market outlook across the 7MM during the forecast period (2021–2032)?
  • What would be the COPD market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

COPD Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of COPD?
  • What is the historical COPD patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of COPD at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to COPD?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of COPD during the forecast period (2021–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of COPD along with the approved therapy?
  • What are the current treatment guidelines for the treatment of COPD in the US and Europe?
  • What are the COPD marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of COPD?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of COPD?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COPD therapies?
  • What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for COPD and their status?
  • What are the key designations that have been granted for the emerging therapies for COPD?
  • What are the 7MM historical and forecasted market of COPD?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the COPD.
  • To understand the future market competition in the COPD market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for COPD in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the COPD market.
  • To understand the future market competition in the COPD market.

Frequently Asked Questions

What is Chronic Obstructive Pulmonary Disease?
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
What is the Chronic Obstructive Pulmonary Disease Market Size in 7MM?
The total Chronic Obstructive Pulmonary Disease market size was accounted for USD 12,333 Million in the year 2020 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Chronic Obstructive Pulmonary Disease Market Landscape?
The key players in the Chronic Obstructive Pulmonary Disease market who are in different phases of developing Chronic Obstructive Pulmonary Disease Therapies are AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Tetherex Pharmaceuticals Corporation, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.
What are the Key strengths of the Chronic Obstructive Pulmonary Disease Market Report?
Key strengths of the Chronic Obstructive Pulmonary Disease Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Chronic Obstructive Pulmonary Disease Market.
Which country is expected to account for the most significant prevalent cases for Chronic Obstructive Pulmonary Disease in the 7MM?
The United States is expected to account for the highest prevalent Chronic Obstructive Pulmonary Disease cases.

1. Key Insights

2. Report Introduction

3. Chronic Obstructive Pulmonary Disease (COPD) Market Overview at a Glance

3.1. Market Share (%) Distribution of COPD by Class in 2019

3.2. Market Share (%) Distribution of COPD by Class in 2032

4. Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Factors That Influence Disease Development and Progression

6.3. Symptoms

6.4. Types

6.5. Classification

6.6. Stages

6.7. Pathology, Pathogenesis, and Pathophysiology

6.8. Diagnosis

6.8.1. Differential Diagnosis

6.8.2. Diagnostic Algorithm

6.8.3. Diagnostic Guidelines

6.8.3.1. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

6.8.3.2. Chronic Obstructive Pulmonary Disease: Diagnosis and Management

6.8.3.3. Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition

6.9. Treatment and Management

6.10. Treatment Algorithm Chronic obstructive pulmonary disease (COPD)

6.11. Guidelines

6.11.1. Chronic Obstructive Pulmonary Disease in over 16s: Nonpharmacological Management and Use of Inhaled Therapies: NICE

6.11.2. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline 2020

6.11.3. Global Initiative for Chronic Obstructive Lung Disease Guideline 2021

6.12. Vaccination in COPD

6.12.1. Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition: The Japanese Respiratory Society

6.12.2. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment Guideline: Kaiser Foundation Health Plan of Washington

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.3.1. US Assumptions and Rationale

7.3.2. EU5 Assumptions and Rationale

7.3.3. JP Assumptions and Rationale

7.4. Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM

7.5. The United States

7.5.1. Diagnosed Prevalent Cases of COPD in the United States

7.5.2. Gender-specific Diagnosed Prevalent Cases of COPD in the United States

7.5.3. Age-specific Diagnosed Prevalent Cases of COPD in the United States

7.5.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States

7.5.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States

7.6. Europe

7.6.1. Diagnosed Prevalent Cases of COPD in Europe

7.6.2. Gender-specific Diagnosed Prevalent Cases of COPD in Europe

7.6.3. Age-specific Diagnosed Prevalent Cases of COPD in Europe

7.6.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe

7.6.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe

7.7. Japan

7.7.1. Diagnosed Prevalent Cases of COPD in Japan

7.7.2. Gender-specific Diagnosed Prevalent Cases of COPD in Japan

7.7.3. Age-specific Diagnosed Prevalent Cases of COPD in Japan

7.7.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan

7.7.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan

8. Patient Journey

9. Organizations contributing towards Chronic Obstructive Pulmonary Disease (COPD)

10. Marketed Therapies

10.1. Duaklir Pressair/Duaklir Genuair (Aclidinium Bromide and Formoterol Fumarate): AstraZeneca/Circassia Pharmaceuticals Inc.

10.1.1. Product Description

10.1.2. Regulatory Milestones

10.1.3. Other Developmental activities

10.1.4. Clinical Development

10.1.5. Clinical Trials Information

10.1.6. Safety and Efficacy

10.1.7. Product Profile

10.2. Advair Diskus/Adoair Diskus/Seretide Diskus (Fluticasone Propionate and Salmeterol Xinafoate): GlaxoSmithKline

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Other Developmental activities

10.2.4. Clinical Development

10.2.5. Clinical Trials Information

10.2.6. Safety and Efficacy

10.2.7. Product Profile

10.3. Symbicort (Budesonide and Formoterol Fumarate Dihydrate): AstraZeneca

10.3.1. Product Description

10.3.2. Regulatory Milestones

10.3.3. Other Developmental activities

10.3.4. Clinical Development

10.3.5. Clinical Trials Information

10.3.6. Safety and Efficacy

10.3.7. Product Profile

10.4. Anoro Ellipta (Umeclidinium Bromide and Vilanterol Trifenatate): GlaxoSmithKline/Theravance, Inc/Innoviva

10.4.1. Product Description

10.4.2. Regulatory Milestones

10.4.3. Other Developmental activities

10.4.4. Clinical Development

10.4.5. Clinical Trials Information

10.4.6. Safety and Efficacy

10.4.7. Product Profile

10.5. Incruse Ellipta/Encruse Ellipta (Umeclidinium Inhalation Powder): GlaxoSmithKline

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Other Developmental activities

10.5.4. Clinical Development

10.5.5. Clinical Trials Information

10.5.6. Safety and Efficacy

10.5.7. Product Profile

10.6. Trydonis (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate, and Glycopyrronium): Chiesi Farmaceutici

10.6.1. Product Description

10.6.2. Regulatory Milestones

10.6.3. Other Developmental Activities

10.6.4. Clinical Development

10.6.5. Clinical Trials Information

10.6.6. Safety and Efficacy

10.6.7. Product Profile

10.7. Bevespi Aerosphere (Glycopyrronium/Formoterol Fumarate): AstraZeneca

10.7.1. Product Description

10.7.2. Regulatory Milestones

10.7.3. Other Developmental Activities

10.7.4. Clinical Development

10.7.5. Clinical Trials Information

10.7.6. Safety and Efficacy

10.7.7. Product Profile

10.8. Brovana (Arformoterol tartrate): Sunovion Pharmaceuticals

10.8.1. Product Description

10.8.2. Regulatory Milestones

10.8.3. Other Developmental Activities

10.8.4. Safety and Efficacy

10.8.5. Product Profile

10.9. Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder): Boehringer Ingelheim Pharmaceuticals

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Other Developmental Activities

10.9.4. Safety and Efficacy

10.9.5. Product Profile

10.10. Eklira Genuair/Tudorza Pressair/Betrays Genuair (Aclidinium Bromide Inhalation Powder): AstraZeneca

10.10.1. Product Description

10.10.2. Regulatory Milestones

10.10.3. Other Developmental Activities

10.10.4. Clinical Development

10.10.5. Clinical Trials Information

10.10.6. Safety and Efficacy

10.10.7. Product Profile

10.11. Breztri Aerosphere/Trixeo Aerosphere (Budesonide/Glycopyrrolate/Formoterol Fumarate): AstraZeneca

10.11.1. Product Description

10.11.2. Regulatory Milestones

10.11.3. Other Developmental Activities

10.11.4. Clinical Development

10.11.5. Clinical Trials Information

10.11.6. Safety and Efficacy

10.11.7. Product Profile

10.12. Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/ Vilanterol): GlaxoSmithKline

10.12.1. Product Description

10.12.2. Regulatory Milestones

10.12.3. Other Developmental activities

10.12.4. Clinical Development

10.12.5. Clinical Trials Information

10.12.6. Safety and Efficacy

10.12.7. Product Profile

10.13. Breo Ellipta/Relvar Ellipta (Fluticasone Furoate and Vilanterol): GlaxoSmithKline

10.13.1. Product Description

10.13.2. Regulatory Milestones

10.13.3. Other Developmental activities

10.13.4. Safety and Efficacy

10.13.5. Product Profile

11. Emerging Drugs

11.1. Key Cross Competition

11.2. Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.3. Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

11.3.1. Drug Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Product Profile

11.3.6. Analysts’ Views

11.4. Tyvaso (Inhaled treprostinil solution): United Therapeutics

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Product Profile

11.5. Ensifentrine (RPL554): Verona Pharma PLC

11.5.1. Product Description

11.5.2. Other Developmental Activities

11.5.3. Clinical Development

11.5.4. Clinical Trials Information

11.5.5. Safety and Efficacy

11.5.6. Product Profile

11.5.7. Analysts’ Views

11.6. Fasenra (Benralizumab): AstraZeneca

11.6.1. Drug Description

11.6.2. Other Developmental Activities

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Safety and Efficacy

11.6.6. Product Profile

11.6.7. Analysts’ Views

11.7. CHF6001 (Tanimilast): Chiesi Farmaceutici S.p.A.

11.7.1. Drug Description

11.7.2. Clinical Development

11.7.3. Clinical Trials Information

11.7.4. Safety and Efficacy

11.7.5. Product Profile

11.8. Nucala (Mepolizumab): GlaxoSmithKline

11.8.1. Drug Description

11.8.2. Other Developmental Activities

11.8.3. Clinical Development

11.8.4. Clinical Trials Information

11.8.5. Safety and Efficacy

11.8.6. Product Profile

11.8.7. Analysts’ Views

11.9. MV130 (Bactek): Inmunotek

11.9.1. Product Description

11.9.2. Clinical Development

11.9.3. Clinical Trials Information

11.9.4. Safety and Efficacy

11.9.5. Product Profile

11.10. MEDI3506: AstraZeneca

11.10.1. Product Description

11.10.2. Other Developmental Activities

11.10.3. Clinical Development

11.10.4. Clinical Trials Information

11.10.5. Product Profile

11.11. SelK2: Tetherex Pharmaceuticals Corporation

11.11.1. Product Description

11.11.2. Other Developmental Activities

11.11.3. Clinical Development

11.11.4. Clinical Trials Information

11.11.5. Product Profile

11.12. Epeleuton (DS102): Afimmune

11.12.1. Product Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.4. Clinical Trials Information

11.12.5. Product Profile

11.13. NOV-14 (CSJ117): Novartis Pharmaceuticals

11.13.1. Product Description

11.13.2. Other Developmental Activities

11.13.3. Clinical Development

11.13.4. Clinical Trials Information

11.13.5. Product Profile

11.14. Zofin: Organicell Regenerative Medicine

11.14.1. Product Description

11.14.2. Other Developmental Activities

11.14.3. Clinical Development

11.14.4. Clinical Trials Information

11.14.5. Product Profile

11.15. NTHi Mcat investigational vaccine (GSK3277511A): GlaxoSmithKline

11.15.1. Product Description

11.15.2. Clinical Development

11.15.3. Clinical Trials Information

11.15.4. Safety and Efficacy

11.15.5. Product Profile

11.16. Icenticaftor (QBW251): Novartis Pharmaceuticals

11.16.1. Product Description

11.16.2. Clinical Development

11.16.3. Clinical Trials Information

11.16.4. Safety and Efficacy

11.16.5. Product Profile

11.17. Kalydeco (Ivacaftor/VX-770): Vertex Pharmaceuticals Incorporated

11.17.1. Product Description

11.17.2. Clinical Development

11.17.3. Clinical Trials Information

11.17.4. Safety and Efficacy

11.17.5. Product Profile

11.18. PUL-042 Inhalation Solution: Pulmotect Inc.

11.18.1. Drug Description

11.18.2. Other Developmental Activities

11.18.3. Clinical Development

11.18.4. Clinical Trials Information

11.18.5. Product Profile

11.19. Benlysta (Belimumab): GlaxoSmithKline

11.19.1. Drug Description

11.19.2. Other Developmental Activities

11.19.3. Clinical Development

11.19.4. Clinical Trials Information

11.19.5. Product Profile

11.20. Azithromycin: Genentech

11.20.1. Drug Description

11.20.2. Clinical Development

11.20.3. Clinical Trials Information

11.20.4. Product Profile

11.21. Tezepelumab: AstraZeneca/Amgen

11.21.1. Drug Description

11.21.2. Other Developmental Activities

11.21.3. Clinical Development

11.21.4. Clinical Trials Information

11.21.5. Product Profile

11.22. Acumapimod (BCT-197): Mereo BioPharma

11.22.1. Drug Description

11.22.2. Other Developmental Activities

11.22.3. Clinical Development

11.22.4. Clinical Trials Information

11.22.5. Safety and Efficacy

11.22.6. Product Profile

11.23. BIO-11006 Inhalation Solution: Biomarck Pharmaceuticals

11.23.1. Drug Description

11.23.2. Other Developmental Activities

11.23.3. Clinical Development

11.23.4. Clinical Trials Information

11.23.5. Safety and Efficacy

11.23.6. Product Profile

12. Potential of Emerging and Current therapies

13. Chronic Obstructive Pulmonary Disease (COPD): Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Chronic Obstructive Pulmonary Disease in the 7MM

13.3. Market Size by Therapies of Chronic Obstructive Pulmonary Disease

13.3.1. Market Size of Chronic Obstructive Pulmonary Disease by Class

13.4. Key Market Forecast Assumptions

13.5. Attribute Analysis

13.6. Market Outlook

13.7. Market size of Chronic Obstructive Pulmonary Disease in the United States

13.7.1. Total Market size of Chronic Obstructive Pulmonary Disease

13.7.2. Market Size by Therapies of Chronic Obstructive Pulmonary Disease

13.7.2.1. Market Size of Chronic Obstructive Pulmonary Disease by Class

13.7.2.2. Market Size of Chronic Obstructive Pulmonary Disease by Therapies

13.8. Market size of Chronic Obstructive Pulmonary Disease in EU-5

13.8.1. Total Market size of Chronic Obstructive Pulmonary Disease in EU5

13.8.2. Market Size by Chronic Obstructive Pulmonary Disease by Class in EU5

13.8.2.1. Germany

13.8.2.2. France

13.8.2.3. Italy

13.8.2.4. Spain

13.8.2.5. United Kingdom

13.8.3. Market Size by Chronic Obstructive Pulmonary Disease by Therapies in EU5

13.8.3.1. Germany

13.8.3.2. France

13.8.3.3. Italy

13.8.3.4. Spain

13.8.3.5. United Kingdom

13.9. Market size of Chronic Obstructive Pulmonary Disease in Japan

13.9.1. Total Market size of Chronic Obstructive Pulmonary Disease

13.9.2. Market Size by Therapies of Chronic Obstructive Pulmonary Disease

13.9.2.1. Market Size of Chronic Obstructive Pulmonary Disease by Class

13.9.2.2. Market Size of Chronic Obstructive Pulmonary Disease by Therapies

14. KOL Views

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Unmet Needs

19. Reimbursement and Market Access

19.1. United States

19.2. Europe

19.3. Japan

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of COPD Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: COPD Classification According to Symptom and Severity Risk

Table 4: Key Indicators for Considering a Diagnosis for COPD

Table 5: Classification of Airflow Limitation Severity in COPD (Based on Post-bronchodilator FEV1)

Table 6: Differential Diagnosis of COPD

Table 7: Pharmacological Characteristics of Approved Bronchodilators for COPD Treatment

Table 8: Pharmacological Treatment of COPD Based on Phenotypes and Disease Severity (GOLD stage I–IV)

Table 9: Antibiotic Dosing for Treatment of COPD Exacerbations

Table 10: Pharmacologic Options That are not Recommended for COPD

Table 11: Key points

Table 12: Vaccination For Stable COPD

Table 13: Total Diagnosed Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM (2019–2032)

Table 14: Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Table 15: Gender-specific Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Table 16: Age-specific Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Table 17: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States (2019–2032)

Table 18: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States (2019–2032)

Table 19: Diagnosed Prevalent Cases of COPD in Europe (2019–2032)

Table 20: Gender-specific Diagnosed Prevalent Cases of COPD in Europe (2019–2032)

Table 21: Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease in Europe (2019–2032)

Table 22: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe (2019–2032)

Table 23: COPD Classification Based on Symptoms and Exacerbation History in Europe (2019–2032)

Table 24: Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Table 25: Gender-specific Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Table 26: Age-specific Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Table 27: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan (2019–2032)

Table 28: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan (2019–2032)

Table 29: Organizations contributing toward COPD

Table 30: Comparison of Approved Drugs for COPD (1/4)

Table 31: Comparison of approved drugs for COPD (2/4)

Table 32: Comparison of approved drugs for COPD (3/4)

Table 33: Comparison of approved drugs for COPD (4/4)

Table 34: Duaklir Pressair/Duaklir Genuair, Clinical Trial Description, 2021

Table 35: Advair Diskus, Clinical Trial Description, 2021

Table 36: Symbicort, Clinical Trial Description, 2021

Table 37: Anoro Ellipta, Clinical Trial Description, 2021

Table 38: Incruse Ellipta, Clinical Trial Description, 2021

Table 39: Trydonis, Clinical Trial Description, 2021

Table 40: Glycopyrronium/formoterol fumarate, Clinical Trial Description, 2021

Table 41: Eklira Genuair/Tudorza Pressair/Bretaris Genuair, Clinical Trial Description, 2021

Table 42: Breztri Aerosphere/Trixeo Aerosphere, Clinical Trial Description, 2021

Table 43: Trelegy Ellipta, Clinical Trial Description, 2021

Table 44: Comparison of emerging drugs under development

Table 45: Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb), Clinical Trial Description, 2021

Table 46: Dupixent (Dupilumab/SAR231893), Clinical Trial Description, 2021

Table 47: Tyvaso (Inhaled Treprostinil Solution), Clinical Trial Description, 2021

Table 48: Ensifentrine, Clinical Trial Description, 2021

Table 49: Fasenra (Benralizumab), Clinical Trial Description, 2021

Table 50: CHF6001 (Tanimilast), Clinical Trial Description, 2021

Table 51: Nucala (Mepolizumab), Clinical Trial Description, 2021

Table 52: MV130 (Bactek), Clinical Trial Description, 2021

Table 53: MEDI3506, Clinical Trial Description, 2021

Table 54: SelK2, Clinical Trial Description, 2021

Table 55: Epeleuton (DS102), Clinical Trial Description, 2021

Table 56: NOV-14 (CSJ117), Clinical Trial Description, 2021

Table 57: Zofin, Clinical Trial Description, 2021

Table 58: NTHi Mcat investigational vaccine (GSK3277511A), Clinical Trial Description, 2021

Table 59: Icenticaftor (QBW251), Clinical Trial Description, 2021

Table 60: Kalydeco (Ivacaftor/VX-770), Clinical Trial Description, 2021

Table 61: PUL-042 Inhalation Solution, Clinical Trial Description, 2021

Table 62: Benlysta (Belimumab), Clinical Trial Description, 2021

Table 63: Azithromycin, Clinical Trial Description, 2021

Table 64: Tezepelumab, Clinical Trial Description, 2021

Table 65: Acumapimod, Clinical Trial Description, 2021

Table 66: BIO-11006, Clinical Trial Description, 2021

Table 67: Market Size of Chronic Obstructive Pulmonary Disease in the 7MM in USD Million (2019–2032)

Table 68: Market Size of Chronic Obstructive Pulmonary Disease by Class in the 7MM, in USD Million (2019–2032)

Table 69: Key Market Forecast Assumptions for Itepekimab

Table 70: Key Market Forecast Assumptions for Ensifentrine

Table 71: Key Market Forecast Assumptions for Dupilumab

Table 72: Key Market Forecast Assumptions for Benralizumab

Table 73: Key Market Forecast Assumptions for Mepolizumab

Table 74: Key Market Forecast Assumptions for CHF6001/Tanimilast

Table 75: Key Market Forecast Assumptions for Acumapimod (BCT-197)

Table 76: Key Market Forecast Assumptions for MV130

Table 77: United States Market Size of Chronic Obstructive Pulmonary Disease in USD Million (2019–2032)

Table 78: Market Size of Chronic Obstructive Pulmonary Disease by Class in the United States, in USD Million (2019–2032)

Table 79: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in the United States, in USD Million (2019–2032)

Table 80: EU-5 Market Size of Chronic Obstructive Pulmonary Disease in USD Million (2019–2032)

Table 81: Market Size of Chronic Obstructive Pulmonary Disease by Class in EU5, in USD Million (2019–2032)

Table 82: Market Size of Chronic Obstructive Pulmonary Disease by Class in Germany, in USD Million (2019–2032)

Table 83: Market Size of Chronic Obstructive Pulmonary Disease by Class in France, in USD Million (2019–2032)

Table 84: Market Size of Chronic Obstructive Pulmonary Disease by Class in Italy, in USD Million (2019–2032)

Table 85: Market Size of Chronic Obstructive Pulmonary Disease by Class in Spain, in USD Million (2019–2032)

Table 86: Market Size of Chronic Obstructive Pulmonary Disease by Class in the UK, in USD Million (2019–2032)

Table 87: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in EU-5, in USD Million (2019–2032)

Table 88: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Germany, in USD Million (2019–2032)

Table 89: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in France, in USD Million (2019–2032)

Table 90: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Italy, in USD Million (2019–2032)

Table 91: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Spain, in USD Million (2019–2032)

Table 92: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in the UK, in USD Million (2019–2032)

Table 93: Market Size of Chronic Obstructive Pulmonary Disease in Japan, in USD Million (2019–2032)

Table 94: Market Size of Chronic Obstructive Pulmonary Disease by Class in Japan, in USD Million (2019–2032)

Table 95: Market Size of Chronic Obstructive Pulmonary Disease by Therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: Etiology, Pathobiology, Pathology of COPD Leading to Airflow Limitation and Clinical Manifestations

Figure 2: Types of COPD – Emphysema and Chronic Bronchitis

Figure 3: Pathways of the Diagnosis of COPD

Figure 4: Spirometry Tracing in Normal Individual Versus Spirometry Tracing Typical of a Patient With Obstructive Disease

Figure 5: ABCD Assessment Tool

Figure 6: Diagnostic Algorithm of the Clinical Phenotypes

Figure 7: Flowchart for the Treatment of Stable Chronic Obstructive Pulmonary Disease (COPD)

Figure 8: Bronchodilator Therapy for Patients With Confirmed, Stable COPD

Figure 9: Algorithm for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Figure 10: Follow-up Pharmacological Treatment

Figure 11: Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM (2019–2032)

Figure 12: Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Figure 13: Gender-specific Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Figure 14: Age-specific Diagnosed Prevalent Cases of COPD in the United States (2019–2032)

Figure 15: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States (2019–2032)

Figure 16: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States (2019–2032)

Figure 17: Diagnosed Prevalent Cases of COPD in Europe (2019–2032)

Figure 18: Gender-specific Diagnosed Prevalent Cases of COPD in Europe (2019–2032)

Figure 19: Age-specific Diagnosed Prevalent Cases of COPD in Europe (2019–2032)

Figure 20: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe (2019–2032)

Figure 21: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe (2019–2032)

Figure 22: Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Figure 23: Gender-specific Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Figure 24: Age-specific Diagnosed Prevalent Cases of COPD in Japan (2019–2032)

Figure 25: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan (2019–2032)

Figure 26: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan (2019–2032)

Figure 27: Patient Journey

Figure 28: Market Size of Chronic Obstructive Pulmonary Disease in the 7MM in USD Million (2019–2032)

Figure 29: Market Size of Chronic Obstructive Pulmonary Disease by Class in the 7MM, in USD Million (2019–2032)

Figure 30: Market Size of Chronic Obstructive Pulmonary Disease in the United States, USD Millions (2019–2032)

Figure 31: Market Size of Chronic Obstructive Pulmonary Disease by Class in the United States, in USD Million (2019–2032)

Figure 32: Market Size of Chronic Obstructive Pulmonary Disease in EU5, USD Millions (2019–2032)

Figure 33: Market Size of Chronic Obstructive Pulmonary Disease by Class in EU5, in USD Million (2019–2032)

Figure 34: Market Size of Chronic Obstructive Pulmonary Disease in Japan, USD Millions (2019–2032)

Figure 35: Market Size of Chronic Obstructive Pulmonary Disease by Class in Japan, in USD Million (2019–2032)

AstraZeneca/Circassia Pharmaceuticals Inc.
 GlaxoSmithKline
 AstraZeneca
 GlaxoSmithKline/Theravance, Inc/Innoviva
 GlaxoSmithKline
 Chiesi Farmaceutici
 AstraZeneca
 Sunovion Pharmaceuticals
 Boehringer Ingelheim Pharmaceuticals
 AstraZeneca
 AstraZeneca
 GlaxoSmithKline
 GlaxoSmithKline
 Sanofi/Regeneron Pharmaceuticals
 Regeneron Pharmaceuticals/Sanofi
 United Therapeutics
 Verona Pharma PLC
 AstraZeneca
 Chiesi Farmaceutici S.p.A.
 GlaxoSmithKline
 Inmunotek
 AstraZeneca
 Tetherex Pharmaceuticals Corporation
 Novartis Pharmaceuticals
 Organicell Regenerative Medicine
 GlaxoSmithKline
 Novartis Pharmaceuticals
 Vertex Pharmaceuticals Incorporated
 Pulmotect Inc.
 GlaxoSmithKline
 Genentech
 AstraZeneca/Amgen
 Mereo BioPharma
 Biomarck Pharmaceuticals

 

Forward to Friend

Need A Quote